| Literature DB >> 24713049 |
Andrew J E Seely, Andrea Bravi, Christophe Herry, Geoffrey Green, André Longtin, Tim Ramsay, Dean Fergusson, Lauralyn McIntyre, Dalibor Kubelik, Donna E Maziak, Niall Ferguson, Samuel M Brown, Sangeeta Mehta, Claudio Martin, Gordon Rubenfeld, Frank J Jacono, Gari Clifford, Anna Fazekas, John Marshall.
Abstract
INTRODUCTION: Prolonged ventilation and failed extubation are associated with increased harm and cost. The added value of heart and respiratory rate variability (HRV and RRV) during spontaneous breathing trials (SBTs) to predict extubation failure remains unknown.Entities:
Mesh:
Year: 2014 PMID: 24713049 PMCID: PMC4057494 DOI: 10.1186/cc13822
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flow diagram of selection of patients. Beside standard exclusions due to protocol and technical violations, the diagram shows how the dataset was reduced to ensure proper variability computation. In particular, patients were excluded when (1) having less than two windows of both heart rate and respiratory rate variability to analyze prior and during the spontaneous breathing trial, and (2) variability was extracted from waveforms deemed to be poor quality.
Patient demographics
| | |||
|---|---|---|---|
| Gender: | | | |
| Males, n (%) | 186 (48.6) | 29 (56.7) | 0.27 |
| Females, n (%) | 191 (49.9) | 21 (41.2) | 0.24 |
| Age (95% CI) | 63 (61, 64) | 65 (58, 69) | 0.86 |
| APACHE II score (95% CI) | 19 (19, 20) | 20 (18, 23) | 0.21 |
| Level of sedationx (95% CI) | 0 (0, 0) | 0 (−1, 0) | 0.78 |
| ICU admission diagnoses | | | |
| Cardiovascular, n (%) | 112 (25.4) | 12 (20.0) | 0.40 |
| Respiratory, n (%) | 87 (19.7) | 18 (30.0) | 0.05 |
| Infections, n (%) | 62 (14.1) | 10 (16.7) | 0.54 |
| Gastrointestinal, n (%) | 34 (7.7) | 3 (5.0) | - |
| Surgery, n (%) | 33 (7.5) | 3 (5.0) | - |
| Head, n (%) | 36 (8.2) | 1 (1.7) | - |
| Renal, n (%) | 18 (4.1) | 2 (3.3) | - |
| Trauma, n (%) | 8 (1.8) | 1 (1.7) | - |
| Overdose, n (%) | 9 (2.0) | 1 (1.7) | - |
| Pancreatitis, n (%) | 3 (0.7) | 1 (1.7) | - |
| Hepatobiliar, n (%) | 5 (1.1) | 0 (0.0) | - |
| Other, n (%) | 34 (7.7) | 8 (13.3) | 0.12 |
| Comorbidities+: | | | |
| None, n (%) | 237 (61.9) | 28 (54.9) | 0.34 |
| Lung, n (%) | 90 (23.5) | 15 (29.4) | 0.35 |
| Heart, n (%) | 81 (21.1) | 13 (25.5) | 0.48 |
| Both, n (%) | 25 (6.5) | 5 (9.8) | 0.39 |
| Ventilation settings pre-SBT: | | | |
| PEEP (95% CI) (cm H2O) | 10 (8 10) | 8 (8 10) | 0.90 |
| PS (95% CI) (cm H2O) | 10 (10 10) | 10 (10 10) | 0.14 |
| FiO2, (95% CI) | 30 (30 30) | 30 (30 30) | 0.04 |
| Ventilation settings during SBT: | | | |
| PEEP (95% CI) (cm H2O) | 5 (5 5) | 5 (5 5) | 0.46 |
| PS (95% CI) (cm H2O) | 5 (5 5) | 5 (5 5) | 0.01 |
| FiO2, (95% CI) | 30 (30 30) | 30 (30 30) | 0.11 |
| Perceived risk of failure: | | | |
| N/A, n (%) | 53 (13.8) | 7 (13.7) | 0.98 |
| Low, n (%) | 117 (30.5) | 6 (11.7) | 0.005 |
| Average, n (%) | 180 (47.0) | 26 (51.1) | 0.59 |
| High, n (%) | 33 (8.7) | 12 (23.5) | 0.001 |
| Respiratory rate: [breaths/min] | | | |
| Pre-SBT (95% CI) | 16.0 (16.0, 18.0) | 18.0 (15.0, 22.0) | 0.09 |
| During SBT (95% CI) | 18.4 (17.9, 19.0) | 21.7 (18.7, 25.0) | 0.005 |
| RSBI: [breaths/min/L] | | | |
| Pre-SBT (95% CI) | 34.1 (31.8, 36.4) | 40.0 (32.5, 50.0) | 0.16 |
| During SBT (95% CI) | 42.7 (39.3, 45.6) | 46.6 (40.0, 67.5) | 0.005 |
Low, average and high-risk categories were based on clinical impression. ^There is a maximum amount of 2% of missing values in each category, due to clinical data not recorded (for example males and females in the failed population add up to 50, instead of 51); *comparison between passed and failed using Wilcoxon rank-sum test to compare the medians, or chi-square test to compare the proportions (no P value was provided for those variables with less than five samples); xcomputed through Richmond agitation-sedation scale (RASS) score; +heart comorbidities are coronary artery bypass graft, dilated cardiomyopathy, congestive heart failure, and coronary artery disease; lung comorbidities are pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), asthma; ‘None’ corresponds to no lung or heart comorbidities. APACHE II, acute physiology and chronic health evaluation II; ICU, intensive care unit; SBT, spontaneous breathing trial; PEEP, positive end-expiratory pressure; PS, pressure support; FiO2, fraction of inspired oxygen.
Statistically significant comparisons of during spontaneous breathing trial (SBT) variability
| Statistical | HRV Mean of the differences | 1.4 10−6 (−9.4 10−7, 3.7 10−6) | −8.4 10−6 (−1.5 10−5, −1.9 10−6) | 0.00278 |
| Geometric | RRV Recurrence quantification analysis: average diagonal line | 0.0057 (0.0054, 0.0060) | 0.0044 (0.0038, 0.0053) | 0.00011 |
| | RRV Recurrence quantification analysis: maximum diagonal line | 0.021 (0.020, 0.022) | 0.016 (0.015, 0.018) | 0.00004 |
| | RRV Recurrence quantification analysis: maximum vertical line | 0.017 (0.016, 0.018) | 0.012 (0.011, 0.014) | 0.00017 |
| | RRV Recurrence quantification analysis: trapping time | 0.0048 (0.0046, 0.0050) | 0.0038 (0.0030, 0.0042) | 0.00009 |
| Informational | RRV Fano factor distance from a Poisson distribution | −0.12 (−0.12, −0.11) | −0.15 (−0.17, −0.12) | 0.00166 |
| Energetic | RRV Hjorth parameters: activity | 11.1 (10.4, 11.8) | 7.8 (6.0, 10.7) | 0.00406 |
| Invariant | HRV Power Law (based on frequency) x intercept | 15.8 (14.8, 17.3) | 10.0 (4.5, 13.9) | 0.00255 |
| | RRV Largest Lyapunov exponent | 1.02 (1.00, 1.02) | 1.07 (1.03, 1.14) | 0.00151 |
| RRV Power Law (based on histogram) y intercept | −2.17 (−2.21, −2.10) | −2.35 (−2.59, −2.15) | 0.00259 |
For specific details about each measure, refer to [28]. HRV, heart rate variability; RRV, respiratory rate variability.
Figure 2Distributions of respiratory rate (RR),rapid shallow breathing index (RSBI) and variability. This figure shows the distribution of values for passed and failed of three different measures (from the left: respiratory rate, rapid shallow breathing index, and respiratory rate variability recurrence quantification analysis: maximal diagonal line). Each grey circle represents a subject. The black box with a white line in between represents the median with its 95% confidence interval.
Prognostic accuracy comparison
| Single logistic regression: heart rate | 0.51 | 0.5 | 0.55 | 0.11 | 0.87 | 0.22 |
| Single logistic regression: RSBI | 0.61 | 0.5 | 0.72 | 0.18 | 0.91 | 0.04 |
| Single logistic regression: respiratory rate | 0.63 | 0.5 | 0.66 | 0.17 | 0.91 | 0.04 |
| Ensemble of three univariate logistic regressions: | 0.62 | 0.5 | 0.69 | 0.17 | 0.90 | 0.07 |
| Heart rate, respiratory rate, RSBI | ||||||
| WAVE score | 0.69 | 0.75 | 0.59 | 0.18 | 0.94 | - |
*Positive test for probability of failure equal or above 0.5. ROC AUC, area under the receiver operating characteristic curve; PPV, positive predictive value; NPV, negative predictive value; NRI, net reclassification improvement; RSBI, rapid shallow breathing index; WAVE, weaning and variability evaluation.
Figure 3Weaning and variability evaluation (WAVE) score quartile. This figure shows the risk/fold increase in risk of failing extubation associated with each quartile of the population. The risk is defined as the number of patients who failed divided by the total number of patients in a given quartile. The fold increase in risk is the risk divided by the average risk of failure of the dataset (approximately 12%). The total number of patients is 434, therefore each quartile is representative of 108 patients.
Figure 4Weaning and variability evaluation (WAVE) score, rapid shallow breathing index (RBSI) and clinical impression. These figures show how the risk/fold increase in risk of failing extubation associated with positive WAVE score (that is above 0.5) increases with increasing RSBI during SBT (above), or the clinical impression of the physician at the end of the SBT (below). The risk is defined as the number of patients who failed divided by the total number of patients in a given group (for example, above 0.5). The fold increase in risk is the risk divided by the average risk of failure of the dataset (approximately 12%). There are 396 patients with low RSBI (45 failed, 351 passed), and 26 patients with high RSBI (6 failed, 20 passed), while 12 passed had no RSBI reported. There is no statistically significant difference between the number of failed and passed that had no RSBI reported (P value = 0.2, chi-squared test for proportions). There are 330 patients with low/average risk of failure (32 failed, 298 passed), and 45 with high risk of failure (12 failed, 33 passed), while 7 failed and 52 passed have no perceived risk of failure reported. There is no statistically significant difference between the number of failed and passed that had no perceived risk of failure reported (P value = 0.98, chi-squared test for proportions).